HK1174254A1 - Use of erbb3 inhibitors in the treatment of triple negative breast cancer erbb3 - Google Patents
Use of erbb3 inhibitors in the treatment of triple negative breast cancer erbb3Info
- Publication number
- HK1174254A1 HK1174254A1 HK13101209.0A HK13101209A HK1174254A1 HK 1174254 A1 HK1174254 A1 HK 1174254A1 HK 13101209 A HK13101209 A HK 13101209A HK 1174254 A1 HK1174254 A1 HK 1174254A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- erbb3
- treatment
- breast cancer
- negative breast
- triple negative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31289510P | 2010-03-11 | 2010-03-11 | |
PCT/US2011/028129 WO2011112953A2 (en) | 2010-03-11 | 2011-03-11 | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1174254A1 true HK1174254A1 (en) | 2013-06-07 |
Family
ID=44513103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13101209.0A HK1174254A1 (en) | 2010-03-11 | 2013-01-28 | Use of erbb3 inhibitors in the treatment of triple negative breast cancer erbb3 |
Country Status (21)
Country | Link |
---|---|
US (4) | US8895001B2 (xx) |
EP (2) | EP2544680B1 (xx) |
JP (2) | JP2013522237A (xx) |
KR (1) | KR101798679B1 (xx) |
CN (1) | CN102858335B (xx) |
AU (1) | AU2011224186C1 (xx) |
BR (1) | BR112012022802A2 (xx) |
CA (1) | CA2792327C (xx) |
DK (1) | DK2544680T3 (xx) |
EA (1) | EA201201186A1 (xx) |
ES (1) | ES2535503T3 (xx) |
HK (1) | HK1174254A1 (xx) |
IL (1) | IL221693A (xx) |
MX (1) | MX344355B (xx) |
NZ (1) | NZ602084A (xx) |
PL (1) | PL2544680T3 (xx) |
PT (1) | PT2544680E (xx) |
SG (1) | SG183532A1 (xx) |
UA (1) | UA111149C2 (xx) |
WO (1) | WO2011112953A2 (xx) |
ZA (1) | ZA201206425B (xx) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2129396E (pt) | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
AU2009321508B2 (en) | 2008-11-03 | 2015-03-12 | Adc Therapeutics Sa | Antibodies that specifically block the biological activity of a tumor antigen |
SI2516469T1 (sl) | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
PL2544680T3 (pl) * | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
JP6057896B2 (ja) | 2010-08-20 | 2017-01-11 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
KR20140044796A (ko) * | 2011-03-11 | 2014-04-15 | 메리맥 파마슈티컬즈, 인크. | 호르몬 무반응 유방암의 치료에서 egfr-패밀리 수용체의 저해제의 용도 |
BR112013025198A2 (pt) | 2011-03-31 | 2018-12-04 | Alethia Biotherapeutics Inc. | anticorpos contra antígeno 1 associado a rim e fragmentos de ligação a antígeno do mesmo |
WO2013003037A2 (en) * | 2011-06-30 | 2013-01-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers |
EA028879B1 (ru) | 2011-09-30 | 2018-01-31 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
WO2013052745A1 (en) * | 2011-10-06 | 2013-04-11 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
JP2014534965A (ja) | 2011-10-13 | 2014-12-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | コンパニオン診断を用いた乳癌の治療 |
AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
JP6243345B2 (ja) * | 2011-12-05 | 2017-12-06 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
PL2802351T3 (pl) | 2012-01-09 | 2019-11-29 | Adc Therapeutics Sa | Środki do leczenia potrójnie negatywnego raka piersi |
WO2013155346A1 (en) | 2012-04-11 | 2013-10-17 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
EP2912062A1 (en) * | 2012-10-24 | 2015-09-02 | Yeda Research and Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
WO2014089570A1 (en) * | 2012-12-07 | 2014-06-12 | The General Hospital Corporation | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
WO2015148971A2 (en) * | 2014-03-27 | 2015-10-01 | Research Foundation Of The City University Of New York | Method for detecting or treating triple negative breast cancer |
US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
JP2018513155A (ja) | 2015-04-17 | 2018-05-24 | メリマック ファーマシューティカルズ インコーポレーティッド | セリバンツマブを用いた併用療法 |
US9795624B2 (en) | 2015-05-04 | 2017-10-24 | Research Foundation Of The City University Of New York | Cationic polymers as co-drugs for chemotherapeutic agents |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
ES2826827T3 (es) * | 2015-06-15 | 2021-05-19 | Angiochem Inc | Métodos para el tratamiento de carcinomatosis leptomeníngea |
CN105375955B (zh) * | 2015-10-26 | 2018-07-17 | 西安电子科技大学 | 一种信能同传中继网络中的协作传输方法 |
KR101746152B1 (ko) * | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ErbB3에 특이적으로 결합하는 항체 및 그의 용도 |
CA3007644A1 (en) | 2015-12-11 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade |
AU2017235450A1 (en) | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
CA3056797A1 (en) | 2017-03-16 | 2018-09-20 | Children's Medical Center Corporation | Engineered liposomes as cancer-targeted therapeutics |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
AU2019364258A1 (en) * | 2018-10-21 | 2021-06-03 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
WO2020161614A1 (en) * | 2019-02-05 | 2020-08-13 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods for treating triple negative breast cancer using a human erbb-2 mutant protein |
CN112755173B (zh) * | 2020-12-31 | 2022-01-07 | 深圳市科达顺生物技术有限公司 | 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法 |
CN117412766A (zh) * | 2021-03-11 | 2024-01-16 | 艾利维申肿瘤学公司 | 抗erbb3(her3)单克隆抗体治疗与神经调节蛋白1(nrg1)基因融合相关肿瘤的剂量和给药 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5344760A (en) | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6983227B1 (en) | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
CN1214044C (zh) | 1996-03-27 | 2005-08-10 | 基因技术股份有限公司 | ErbB3抗体 |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
AU722178B2 (en) | 1996-07-12 | 2000-07-27 | Genentech Inc. | Chimeric heteromultimer adhesins |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
US20020002276A1 (en) | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
GB2336695A (en) | 1998-04-20 | 1999-10-27 | Teamware Group Oy | Modelling a work process |
CA2332331A1 (en) | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
ATE438411T1 (de) | 1999-08-27 | 2009-08-15 | Genentech Inc | Dosierung für die behandlung mit anti erbb2- antikörpern |
US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CA2443806A1 (en) | 2000-04-14 | 2002-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
ATE441433T1 (de) | 2000-05-19 | 2009-09-15 | Genentech Inc | Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US6871171B1 (en) | 2000-10-19 | 2005-03-22 | Optimata Ltd. | System and methods for optimized drug delivery and progression of diseased and normal cells |
EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
ATE446317T1 (de) * | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
US7125680B2 (en) | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
AU2002326531A1 (en) | 2001-08-03 | 2003-02-17 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
WO2003014159A1 (en) | 2001-08-03 | 2003-02-20 | Commonwealth Scientific And Industrial Research Organisation | Methods of screening based on the egf receptor crystal structure |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
KR20050038578A (ko) | 2001-10-19 | 2005-04-27 | 파르마 마르, 에스.에이. | 항종양성 화합물의 암치료에 있어서의 향상된 용도 |
US7415359B2 (en) | 2001-11-02 | 2008-08-19 | Gene Network Sciences, Inc. | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents |
AU2003218600C1 (en) | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
US20040132097A1 (en) | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
EP2366718A3 (en) | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
JP4609930B2 (ja) | 2002-12-11 | 2011-01-12 | ベンタナ・メディカル・システムズ・インコーポレーテッド | Her−2指向性治療に対する応答を予測する方法 |
CA2521106A1 (en) | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
WO2005017493A2 (en) | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
US8554486B2 (en) | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
CN101501211A (zh) | 2004-03-31 | 2009-08-05 | 综合医院公司 | 测定癌症对表皮生长因子受体靶向性治疗反应性的方法 |
AU2005249396B2 (en) | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
AU2005249492B2 (en) | 2004-05-27 | 2011-09-22 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
US7794960B2 (en) | 2004-06-04 | 2010-09-14 | Glaxosmithkline Llc | Predictive biomarkers in cancer therapy |
CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
KR101235479B1 (ko) | 2004-08-06 | 2013-02-20 | 제넨테크, 인크. | 바이오마커를 사용한 분석 및 방법 |
EP1789451A4 (en) | 2004-08-12 | 2009-12-02 | Dyax Corp | TIE COMPLEX BINDING PROTEINS |
WO2006044378A2 (en) | 2004-10-12 | 2006-04-27 | University Of Iowa Research Foundation | Rapid computational identification of targets |
US20080254497A1 (en) | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
RU2007125644A (ru) | 2004-12-07 | 2009-01-20 | Дженентек Инк. (Us) | Отбор пациентов для терапии ингибитором her |
US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
RU2007135216A (ru) | 2005-02-23 | 2009-03-27 | Мерримак Фармасьютикалз, Инк. (Us) | Биспецифические связывающие агенты для модулирования биологической активности |
TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
US20090061422A1 (en) | 2005-04-19 | 2009-03-05 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
US20090298061A1 (en) | 2005-07-29 | 2009-12-03 | Siemens Healthcare Diagnostics Inc. | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy |
WO2007041502A2 (en) | 2005-09-30 | 2007-04-12 | Monogram Biosciences | Methods for determining responsiveness to cancer therapy |
KR20080028857A (ko) | 2005-10-05 | 2008-04-01 | 아스트라제네카 유케이 리미티드 | ErbB 수용체 약물에 대한 환자반응을 예측 및 모니터링하는 방법 |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
JP2009532393A (ja) | 2006-04-07 | 2009-09-10 | コペンハーゲン ユニバーシティ | ErbB受容体由来ペプチド断片 |
DK2032982T3 (da) | 2006-05-05 | 2012-11-05 | Univ Yale | Anvendelse af subcellulær lokaliseringsprofiler som prognostiske eller prædiktive indikatorer |
US7709222B2 (en) | 2006-07-13 | 2010-05-04 | Yale University | Methods for making cancer prognoses based on subcellular localization of biomarkers |
US20100158894A1 (en) * | 2006-09-15 | 2010-06-24 | Tokai University | Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same |
US20100178651A1 (en) | 2006-11-03 | 2010-07-15 | Christos Hatzis | Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance |
EP2518508A1 (en) | 2006-11-28 | 2012-10-31 | U3 Pharma GmbH | Activated HER3 as a marker for predicting therapeutic efficacy |
US7825127B2 (en) | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
PT2129396E (pt) | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
ES2529790T3 (es) | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
US20090054051A1 (en) | 2007-08-22 | 2009-02-26 | James Cavallo | Attachable Headset for Portable Device |
CA2721093A1 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
BRPI0917871A2 (pt) * | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
MX336091B (es) | 2009-08-21 | 2016-01-08 | Merrimack Pharmaceuticals Inc | Anticuerpos contra el extodominio de erbb3 y usos de los mismos. |
WO2011047180A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
PL2544680T3 (pl) | 2010-03-11 | 2015-08-31 | Merrimack Pharmaceuticals Inc | Zastosowanie inhibitorów ERBB1 w leczeniu potrójnie ujemnego raka gruczołu sutkowego |
EP2564188A4 (en) | 2010-04-26 | 2013-09-25 | Merrimack Pharmaceuticals Inc | ASSAYS FOR ANTIBODIES AGAINST BIODIENTS USING ABUNDANT ENDOGENIC PROTEIN ANTAGONISTS OF THIS ACTIVE SUBSTANCE |
AU2011274510A1 (en) | 2010-07-09 | 2013-01-24 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
FR2963868B1 (fr) | 2010-08-11 | 2012-09-28 | Valeo Systemes Thermiques | Echangeur de chaleur comprenant un element chauffant serigraphie |
EP2648753A4 (en) | 2010-12-10 | 2015-06-24 | Merrimack Pharmaceuticals Inc | ASSAY AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES |
CN103547598A (zh) | 2011-02-24 | 2014-01-29 | 梅里麦克制药股份有限公司 | 包含抗-erbb3药剂的联合治疗 |
KR20140044796A (ko) * | 2011-03-11 | 2014-04-15 | 메리맥 파마슈티컬즈, 인크. | 호르몬 무반응 유방암의 치료에서 egfr-패밀리 수용체의 저해제의 용도 |
JP2014509593A (ja) | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ErbB経路阻害剤に対する耐性の克服 |
AU2012245491C1 (en) | 2011-04-19 | 2017-12-21 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies |
MX2013012995A (es) | 2011-05-06 | 2014-07-09 | Merrimack Pharmaceuticals Inc | Metodos para prevenir interacciones farmaco-farmaco toxicas en terapias de combinacion que comprenden agentes anti-erbb3. |
AU2012273361A1 (en) | 2011-06-24 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel |
WO2013003037A2 (en) | 2011-06-30 | 2013-01-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers |
WO2013023043A2 (en) * | 2011-08-10 | 2013-02-14 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy |
EP2833915A1 (en) | 2012-04-02 | 2015-02-11 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
CA2975829A1 (en) | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
-
2011
- 2011-03-11 PL PL11730112T patent/PL2544680T3/pl unknown
- 2011-03-11 SG SG2012063905A patent/SG183532A1/en unknown
- 2011-03-11 EA EA201201186A patent/EA201201186A1/ru unknown
- 2011-03-11 CN CN201180013330.9A patent/CN102858335B/zh not_active Expired - Fee Related
- 2011-03-11 WO PCT/US2011/028129 patent/WO2011112953A2/en active Application Filing
- 2011-03-11 MX MX2012010226A patent/MX344355B/es active IP Right Grant
- 2011-03-11 PT PT117301127T patent/PT2544680E/pt unknown
- 2011-03-11 US US13/583,949 patent/US8895001B2/en not_active Expired - Fee Related
- 2011-03-11 CA CA2792327A patent/CA2792327C/en not_active Expired - Fee Related
- 2011-03-11 ES ES11730112.7T patent/ES2535503T3/es active Active
- 2011-03-11 AU AU2011224186A patent/AU2011224186C1/en not_active Ceased
- 2011-03-11 KR KR1020127025753A patent/KR101798679B1/ko active IP Right Grant
- 2011-03-11 NZ NZ602084A patent/NZ602084A/en not_active IP Right Cessation
- 2011-03-11 DK DK11730112T patent/DK2544680T3/en active
- 2011-03-11 EP EP11730112.7A patent/EP2544680B1/en not_active Revoked
- 2011-03-11 EP EP20140196121 patent/EP2859893A1/en not_active Ceased
- 2011-03-11 JP JP2012557285A patent/JP2013522237A/ja active Pending
- 2011-03-11 BR BR112012022802A patent/BR112012022802A2/pt not_active IP Right Cessation
- 2011-11-03 UA UAA201210790A patent/UA111149C2/uk unknown
-
2012
- 2012-08-27 ZA ZA2012/06425A patent/ZA201206425B/en unknown
- 2012-08-30 IL IL221693A patent/IL221693A/en not_active IP Right Cessation
-
2013
- 2013-01-28 HK HK13101209.0A patent/HK1174254A1/xx not_active IP Right Cessation
-
2014
- 2014-10-20 US US14/518,900 patent/US9518130B2/en active Active
-
2016
- 2016-03-09 JP JP2016045111A patent/JP6185102B2/ja not_active Expired - Fee Related
- 2016-11-08 US US15/346,439 patent/US20170291957A1/en not_active Abandoned
-
2018
- 2018-05-31 US US15/994,393 patent/US20190119401A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1174254A1 (en) | Use of erbb3 inhibitors in the treatment of triple negative breast cancer erbb3 | |
HRP20171474T1 (hr) | Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka | |
GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
HK1192758A1 (zh) | '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物 | |
HK1198133A1 (en) | Crizotinib for use in the treatment of cancer | |
IL239007A0 (en) | Use of Aribolin to treat breast cancer | |
HRP20170225T1 (hr) | Fosfoplatini i njihova uporaba za liječenje karcinoma | |
EP2744917A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER | |
SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
ZA201209452B (en) | Gold complexes for use in the treatment of cancer | |
EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
WO2012037553A9 (en) | Use of pkc-iota inhibitors for the treatment of breast cancer | |
HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210314 |